114 related articles for article (PubMed ID: 7490734)
1. Design and synthesis of conformationally constrained analogues of 4-(3-butoxy-4-methoxybenzyl)imidazolidin-2-one (Ro 20-1724) as potent inhibitors of cAMP-specific phosphodiesterase.
Brackeen MF; Cowan DJ; Stafford JA; Schoenen FJ; Veal JM; Domanico PL; Rose D; Strickland AB; Verghese M; Feldman PL
J Med Chem; 1995 Nov; 38(24):4848-54. PubMed ID: 7490734
[TBL] [Abstract][Full Text] [Related]
2. Papaverine and Ro 20-1724 inhibit cyclic nucleotide phosphodiesterase activity and increase cyclic AMP levels in psoriatic epidermis in vitro.
Rusin LJ; Duell EA; Voorhees JJ
J Invest Dermatol; 1978 Aug; 71(2):154-6. PubMed ID: 210235
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of pig aortic smooth muscle cell DNA synthesis by selective type III and type IV cyclic AMP phosphodiesterase inhibitors.
Souness JE; Hassall GA; Parrott DP
Biochem Pharmacol; 1992 Sep; 44(5):857-66. PubMed ID: 1326964
[TBL] [Abstract][Full Text] [Related]
4. Differential modulation of cytokine production by drugs: implications for therapy in heart failure.
Matsumori A; Ono K; Sato Y; Shioi T; Nose Y; Sasayama S
J Mol Cell Cardiol; 1996 Dec; 28(12):2491-9. PubMed ID: 9004165
[TBL] [Abstract][Full Text] [Related]
5. OPC-13013, a cyclic nucleotide phosphodiesterase type III, inhibitor, inhibits cell proliferation and transdifferentiation of cultured rat hepatic stellate cells.
Shimizu E; Kobayashi Y; Oki Y; Kawasaki T; Yoshimi T; Nakamura H
Life Sci; 1999; 64(23):2081-8. PubMed ID: 10372650
[TBL] [Abstract][Full Text] [Related]
6. Type IV phosphodiesterase inhibition improves cardiac contractility in endotoxemic rats.
Thomas NJ; Carcillo JA; Herzer WA; Mi Z; Tofovic SP; Jackson EK
Eur J Pharmacol; 2003 Mar; 465(1-2):133-9. PubMed ID: 12650842
[TBL] [Abstract][Full Text] [Related]
7. Differential inhibitor effects on cyclic adenosine monophosphate-phosphodiesterase isoforms in atopic and normal leukocytes.
Chan SC; Hanifin JM
J Lab Clin Med; 1993 Jan; 121(1):44-51. PubMed ID: 8381148
[TBL] [Abstract][Full Text] [Related]
8. Substituted xanthines, pteridinediones, and related compounds as potential antiinflammatory agents. Synthesis and biological evaluation of inhibitors of tumor necrosis factor alpha.
Cottam HB; Shih H; Tehrani LR; Wasson DB; Carson DA
J Med Chem; 1996 Jan; 39(1):2-9. PubMed ID: 8568809
[TBL] [Abstract][Full Text] [Related]
9. Cyclic AMP-specific phosphodiesterase inhibitor rolipram and RO-20-1724 promoted apoptosis in HL60 promyelocytic leukemic cells via cyclic AMP-independent mechanism.
Zhu WH; Majluf-Cruz A; Omburo GA
Life Sci; 1998; 63(4):265-74. PubMed ID: 9698035
[TBL] [Abstract][Full Text] [Related]
10. (Imidazolylphenyl)pyrrol-2-one inhibitors of cardiac cAMP phosphodiesterase.
Lampe JW; Chou YL; Hanna RG; Di Meo SV; Erhardt PW; Hagedorn AA; Ingebretsen WR; Cantor E
J Med Chem; 1993 Apr; 36(8):1041-7. PubMed ID: 8386770
[TBL] [Abstract][Full Text] [Related]
11. Quaternary substituted PDE4 inhibitors I: the synthesis and in vitro evaluation of a novel series of oxindoles.
Hulme C; Poli GB; Huang FC; Souness JE; Djuric SW
Bioorg Med Chem Lett; 1998 Jan; 8(2):175-8. PubMed ID: 9871649
[TBL] [Abstract][Full Text] [Related]
12. Inotropic responses to selective (RO 20-1724 and SQ 65,442) and nonselective (trequinsin) inhibitors of cyclic AMP-specific class IV phosphodiesterase in newborn, immature, and adult rabbit myocardium.
Oquist NL; Strada SJ; Artman M
Pediatr Res; 1992 Mar; 31(3):300-4. PubMed ID: 1313959
[TBL] [Abstract][Full Text] [Related]
13. Selective effects of phosphodiesterase inhibitors on different phosphodiesterases, adenosine 3',5'-monophosphate metabolism, and lipolysis in 3T3-L1 adipocytes.
Elks ML; Manganiello VC
Endocrinology; 1984 Oct; 115(4):1262-8. PubMed ID: 6207009
[TBL] [Abstract][Full Text] [Related]
14. Selective inhibitors of specific phosphodiesterases in intact adipocytes.
Manganiello V; Degerman E; Elks M
Methods Enzymol; 1988; 159():504-20. PubMed ID: 2457789
[No Abstract] [Full Text] [Related]
15. The type IV phosphodiesterase inhibitors, Ro 20-1724 and rolipram, block the initiation of cocaine self-administration.
Knapp CM; Foye MM; Ciraulo DA; Kornetsky C
Pharmacol Biochem Behav; 1999 Jan; 62(1):151-8. PubMed ID: 9972858
[TBL] [Abstract][Full Text] [Related]
16. A selective inhibitor of cAMP-specific phosphodiesterase, Ro 20-1724, has no effect on the quantal release of acetylcholine from the mouse phrenic nerve.
Chiou LC; Chang CC
J Pharm Pharmacol; 1988 Feb; 40(2):148-9. PubMed ID: 2897454
[TBL] [Abstract][Full Text] [Related]
17. Effects of cAMP-phosphodiesterase isozyme inhibitor on cytokine production by lipopolysaccharide-stimulated human peripheral blood mononuclear cells.
Yoshimura T; Kurita C; Nagao T; Usami E; Nakao T; Watanabe S; Kobayashi J; Yamazaki F; Tanaka H; Nagai H
Gen Pharmacol; 1997 Oct; 29(4):633-8. PubMed ID: 9352314
[TBL] [Abstract][Full Text] [Related]
18. Design, synthesis and structure-activity relationships of a series of 9-substituted adenine derivatives as selective phosphodiesterase type-4 inhibitors.
Raboisson P; Lugnier C; Muller C; Reimund JM; Schultz D; Pinna G; Le Bec A; Basaran H; Desaubry L; Gaudiot F; Seloum M; Bourguignon JJ
Eur J Med Chem; 2003 Feb; 38(2):199-214. PubMed ID: 12620664
[TBL] [Abstract][Full Text] [Related]
19. Differential effects of two phosphodiesterase inhibitors on fat cell metabolism.
Shechter Y
Endocrinology; 1984 Nov; 115(5):1787-91. PubMed ID: 6208014
[TBL] [Abstract][Full Text] [Related]
20. The effects of theophylline and 4-(3-butoxy-4-methoxybenzyl)-2-imidazolidinone (RO 20-1724) on protein secretion from rat parotid gland.
Afari G; Tenenhouse A; Vachon C
Br J Pharmacol; 1982 Nov; 77(3):405-11. PubMed ID: 6291691
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
